Quarterly report
Open the filing on sec.gov
Definium Therapeutics, Inc. (DFTX)
Nasdaq: DFTX · Medicinal Chemicals & Botanical Products · New York, NY · filing with the SEC since 2020
The companyfiscal 2025, as filed
Revenuen/a
Net income-$184M-69.1%
Earnings per share$-2.06-33.8%
Operating cash flow-$132M-66.3%
Cash$258M-5.8%
Debt$40.6M+85.7%
Shareholders’ equity$332M+37.6%
Shares, diluted89.3M+26.8%
Return on equity-55.3%
The recordfrom its filings
Filings in 202690
Newest filingNov 9 · 10-Q
Annual reportFeb 26, 2026
Quarterly reportNov 9, 2026
Next report due10-K by Mar 31
Insider sales, 12 months$7.0M
Insider buys, 12 months$0.00
Patents granted0
Filer categoryNon-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Trailing twelve months to Sep 2026Net income -$337MCash from operations -$191Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Results released
Open the filing on sec.gov
Large holder notice
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Notice of intended sale
Open the filing on sec.gov
Notice of intended sale
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.